| DB ID | MyCo_3252 |
| Title | β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study |
| Year | 2023 |
| PMID | 37823695 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | ICU patients |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The study was approved by the ethics committee of the Friedrich-Alexander-University (FAU) Erlangen-Nürnberg (application number 73_17B). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Here, 41 patients were enrolled, 19 in the intervention group and 22 in the control group. |
| Cohort No. | 41 |
| Age Group | 60 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA, Platelia Candida Ag Plus Assay (Bio-Rad, France) |
| Validation Techniques used | FDA Approved-Fungitell assay, Platelia Candida Ag Plus Assay (Bio-Rad, France) |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
